| Trial ID: | L3431 |
| Source ID: | NCT02185963
|
| Associated Drug: |
Rosuvastatin
|
| Title: |
Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes
|
| Interventions: |
DRUG: Rosuvastatin
|
| Outcome Measures: |
Primary: Functional HDL-C, 1. Cholesterol efflux from macrophages 2. LDL-induced monocyte chemotactic activity (MCA) Assay 3. Quantitation of gene expression of monocyte chemotactic protein-1 (MCP-1), 12 weeks | Secondary: Non-HDL-cholesterol = total cholesterol - HDL-C, 12 weeks|Patients with LDL-C < 70 mg/dl and HDL > 40 mg/dl in men; > 50 in women, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Seoul National University Bundang Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-10
|
| Completion Date: |
2016-05
|
| Results First Posted: |
|
| Last Update Posted: |
2016-05-03
|
| Locations: |
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02185963
|
